We could not find any results for:
Make sure your spelling is correct or try broadening your search.
99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer...
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire CAESAREA, Israel, July 19, 2024 CAESAREA, Israel, July 19, 2024 /PRNewswire/ -- IceCure Medical Ltd...
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer PR Newswire CAESAREA, Israel, July...
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes PR Newswire CAESAREA, Israel, July 1, 2024 CAESAREA, Israel, July...
IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024 PR Newswire CAESAREA, Israel, June 18, 2024 Recent insider...
Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.015 | 5.55555555556 | 0.27 | 0.285 | 0.27 | 40308 | 0.27545878 | CS |
4 | 0.03 | 11.7647058824 | 0.255 | 0.285 | 0.25 | 32098 | 0.26429137 | CS |
12 | 0.05 | 21.2765957447 | 0.235 | 0.285 | 0.2 | 53855 | 0.24699601 | CS |
26 | 0.09 | 46.1538461538 | 0.195 | 0.285 | 0.17 | 45284 | 0.2359168 | CS |
52 | 0.04 | 16.3265306122 | 0.245 | 0.285 | 0.17 | 45787 | 0.22602905 | CS |
156 | -0.395 | -58.0882352941 | 0.68 | 0.69 | 0.17 | 57052 | 0.30052627 | CS |
260 | 0.225 | 375 | 0.06 | 0.95 | 0.03 | 120885 | 0.2183321 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions